Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma
Authors:
Open Access
Abstract
Background: Inhaled corticosteroids (ICS) affect many inflammatory pathways in asthma but have little impact on cysteinyl leukotrienes. This may partly explain persistent airway inflammation during chronic ICS treatment and failure to achieve adequate asthma control in some patients. This double blind, randomised, parallel group, non-inferiority, multicentre 16 week study compared the clinical benefits of adding montelukast to budesonide with doubling the budesonide dose in adults with asthma. Methods: After a 1 month single blind run in period, patients inadequately controlled on inhaled budesonide (800 μg/day) were randomised to receive montelukast 10 mg + inhaled budesonide 800 μg/day (n=448) or budesonide 1600 μg/day (n=441) for 12 weeks. Results: Both groups showed progressive improvement in several measures of asthma control compared with baseline. Mean morning peak expiratory flow (AM PEF) improved similarly in the last 10 weeks of treatment compared with baseline in both the montelukast + budesonide group and in the double dose budesonide group (33.5 v 30.1 l/min). During days 1–3 after start of treatment, the change in AM PEF from baseline was significantly greater in the montelukast + budesonide group than in the double dose budesonide group (20.1 v 9.6 l/min, pConclusion: The addition of montelukast to inhaled budesonide is an effective and well tolerated alternative to doubling the dose of inhaled budesonide in adult asthma patients experiencing symptoms and inadequate control on budesonide alone.Keywords
This publication has 25 references indexed in Scilit:
- Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthmaThorax, 2002
- Effects of Inhaled Glucocorticoids on Bone Density in Premenopausal WomenNew England Journal of Medicine, 2001
- NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist MontelukastAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patientsBMJ, 1999
- Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trialEuropean Respiratory Journal, 1999
- Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthmaThorax, 1999
- Determining a minimal important change in a disease-specific quality of life questionnaireJournal of Clinical Epidemiology, 1994
- Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.Thorax, 1992
- Comparison of dose‐response effects of inhaled beclomethasone dipropionate and budesonide in the management of asthmaAllergy, 1989
- A double‐blind dose‐response study of budesonide by inhalation in patients with bronchial asthmaAllergy, 1988